NCT04139122View on ClinicalTrials.gov

Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

October 5, 2019

Primary Completion Date

March 3, 2020

Study Completion Date

March 3, 2020

Conditions
Dry Eye DiseaseDry Eye Syndrome
Interventions
DRUG

SJP-0132

SJP-0132 is administered as an eye drop

DRUG

Placebo

Placebo is administered as an eye drop

Trial Locations (1)

90630

Senju Investigational Site, Cypress

All Listed Sponsors
lead

Senju Pharmaceutical Co., Ltd.

INDUSTRY

NCT04139122 - Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease | Biotech Hunter | Biotech Hunter